EssilorLuxottica to purchase AI-focused ophthalmology platform Optegra

Published 30/05/2025, 09:36
© Reuters.

Investing.com -- EssilorLuxottica, the Franco-Italian eyewear group and maker of Ray-Ban, announced its plans to acquire Optegra, an AI-focused ophthalmology platform, from MidEuropa. This move is part of the company’s strategy to expand its medical technology portfolio.

On Friday, the eyewear group stated that this acquisition will enhance its current offerings, which already extend beyond frames and lenses. The company also provides AI-powered technologies, wearables, medical instruments, and scientifically proven eyecare solutions.

In the previous year, EssilorLuxottica had expanded its partnership with Meta, Facebook (NASDAQ:META)’s parent company, to create smart Ray-Ban glasses. This collaboration was part of the company’s ongoing efforts to incorporate artificial intelligence into its operations.

Optegra operates more than 70 eye hospitals and diagnostic facilities in the U.K., Czech Republic, Poland, Slovakia, and the Netherlands. The platform offers ophthalmic treatments and elective vision correction procedures, which are supported by artificial intelligence during the pre- and postoperative stages.

The financial details of the transaction have not been disclosed. The completion of the acquisition is expected later this year, pending approval.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.